Showing results (381-390 of 391) with videos related to
Sort By:
Pageof 40
Journal of Multimorbidity and Comorbidity|December 22, 2022
The DynAIRx Project Protocol: Artificial Intelligence for dynamic prescribing optimisation and care integration in multimorbidityLauren E Walker, Aseel S Abuzour, Danushka Bollegala, et al.Nature Communications|June 9, 2023
A multicentric consortium study demonstrates that dimethylarginine dimethylaminohydrolase 2 is not a dimethylarginine dimethylaminohydrolaseVinitha N Ragavan, Pramod C Nair, Natalia Jarzebska, et al.Annals of Surgery|November 13, 2019
Persistent Opioid Use After Combat Injury and Subsequent Long-term Risk of Abuse: A Retrospective Cohort StudyCarl A Beyer, Eduard Poltavskiy, Lauren E Walker, et al.Journal of Multimorbidity and Comorbidity|October 4, 2024
Developing SysteMatic: Prevention, precision and equity by design for people living with multiple long-term conditionsFrances S Mair, Farnaz Nickpour, Barbara Nicholl, et al.Plos One|August 30, 2024
A qualitative exploration of barriers to efficient and effective structured medication reviews in primary care: Findings from the DynAIRx studyAseel S Abuzour, Samantha A Wilson, Alan A Woodall, et al.Journal of Medical Internet Research|January 8, 2026
Developing an AI-Assisted Tool That Identifies Patients With Multimorbidity and Complex Polypharmacy to Improve the Process of Medication Reviews: Qualitative Interview and Focus Group StudyAseel S Abuzour, Samantha A Wilson, Alan A Woodall, et al.Molecules (Basel, Switzerland)|January 8, 2020
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-6Jean Jacques Vanden Eynde, Arduino A Mangoni, Jarkko Rautio, et al.Molecules (Basel, Switzerland)|July 2, 2020
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-7Michael Gütschow, Jean Jacques Vanden Eynde, Josef Jampilek, et al.Clinical Pharmacology and Therapeutics|October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.Nature Communications|November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trialI'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.Pageof 40